4th Meeting of the 190th Session (2010-2011)
In the Augustine United Church
41 George IV Bridge
Edinburgh, EH1 1EL
On Monday 24 January 2011, at 7pm
The strengths and weaknesses of current methods of assessing the safety of prescribed medicines will be discussed as well as data protection, privacy, consent, regulation and ethics (interspersed with singing, art, poetry & philosophy (home-spun and otherwise), fantasy worlds (where are we now) and perfect worlds (will we ever get there?)) and a bit about risks (to individuals) and benefits (to society), duty of care, politics, changing the world, how we can do drug safety better and other random thoughts including expressing ideas that are not my own or new and more singing.
Tom MacDonald is Professor of Clinical Pharmacology and Pharmacoepidemiology in the Division of Medical Sciences, University of Dundee, and honorary consultant physician at Ninewells Hospital and Medical School. His research interests are hypertension, cardiovascular disease and pharmacoepidemiology and drug safety. He is a past president of the International Society of Pharmacoepidemiology, a past member of the pharmacovigilance committee of the committee on safety of medicine and the current director of the Tayside Medicines Monitoring Unit (MEMO) which has access to the MEMO database and to the GPRD database. He is a recent member of the British Hypertension Society Executive Committee and is also the director of the Regional Cardiovascular Risk Clinic (a European Society of Hypertension designated centre of excellence). He also directs the Hypertension Research Centre at Ninewells Hospital and Medical School.
Professor MacDonald has been involved in clinical trials such as ASCOT and he was UK coordinator of the VALUE trial and more recently he is on the executive of the British Hypertension Society, BHF-funded PATHWAY Study. He was also the principal investigator for the 3-D study.
He is currently the principal investigator of two large, multi-national, multi-centre streamlined safety studies; the Standard care versus Celecoxib Outcomes Trial (SCOT) and the Febuxostat versus Allopurinol Safety Trial) FAST.
Professor MacDonald has published extensively on drug safety especially the safety of non steroidal anti-inflammatory drugs (NSAIDs). He has also published many studies of hypertension and other cardiovascular risk factors and cardiovascular disorders.
Members of the Public are welcome to attend
Jane Ridder-Patrick, Secretary
Telephone: 0131 556 2161
The Royal Scottish Society of Arts is Registered Scottish Charity SC015549